Ustekinumab, a human monoclonal antibody targeting IL-12/IL-23, was approved for the treatment of psoriatic arthritis in 2013, but it has shown favorable outcomes in a phase II randomized controlled trial for patients with active lupus [226], and it has been reported to be effective for joint inflammation in patients with SS and RA, although there is still a lack of larger clinical trials [227]. Here, IL23A is linked to psoriatic arthritis.